Pairs a thymic-immune bioregulator with a pineal-neuroendocrine bioregulator as a seasonal "two-axis" longevity course, run together because the founding human trial itself found the combination beat either compound alone on its mortality endpoint (2.5-fold combined vs. 2.0-2.1-fold for Thymalin alone and 1.6-1.8-fold for Epithalamin alone).
Why it matters
Pairs a thymus/immune peptide (Thymalin) with a pineal/sleep-hormone peptide (Epitalon), each aimed at a different aging pathway — the idea being that hitting two separate systems does more than either one alone.
The published per-compound doses, timing, cycle length, the mechanism sources give for why it's combined, and the harm-reduction notes — the parts that took the most research to get right — are part of membership.
